| Not Yet Recruiting | Navigation Intervention for Adolescent and Young Adult Cancer Survivors NCT07406087 | Kaiser Permanente | N/A |
| Not Yet Recruiting | SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer NCT07462663 | Hospital Universitari de Bellvitge | — |
| Not Yet Recruiting | SENTInel Node Mapping Versus Comprehensive Lymphadenectomy in p53-Mutated Endometrial Cancer: A Non-Inferiorit NCT06900582 | University Hospital, Strasbourg, France | N/A |
| Not Yet Recruiting | Adaptive Radiotherapy for Safe Hypofractionation NCT07516210 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 |
| Not Yet Recruiting | Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 NCT07522697 | National Cancer Institute, Naples | Phase 2 |
| Not Yet Recruiting | Signatera Assessment in Early-Stage Endometrial Cancer NCT07339384 | Natera, Inc. | N/A |
| Not Yet Recruiting | MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer NCT07514325 | Radboud University Medical Center | N/A |
| Not Yet Recruiting | Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors NCT06834204 | Rutgers, The State University of New Jersey | N/A |
| Recruiting | A Phase 1 Study of the Safety and Tolerability of CTX-10726 NCT07419841 | Compass Therapeutics | Phase 1 |
| Not Yet Recruiting | Study of EV for Recurrent Endometrial Carcinoma NCT07139977 | William Bradley | Phase 2 |
| Not Yet Recruiting | Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors NCT07524322 | Regor Pharmaceuticals Inc. | Phase 1 |
| Not Yet Recruiting | QLS5132 Combination Therapy in Advanced Solid Tumors NCT07453394 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer NCT07078838 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. NCT07470853 | Whitehawk Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer NCT07369986 | Women's Hospital School Of Medicine Zhejiang University | Phase 2 |
| Recruiting | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871 | Radiopharm Theranostics, Ltd | Phase 1 / Phase 2 |
| Recruiting | Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System NCT07382583 | M.D. Anderson Cancer Center | — |
| Not Yet Recruiting | An Exploratory Study of Detection of Endometrial and Ovarian Cancers in Vaginal Samples Retrieved by the Ellel NCT07429799 | Ellele Health | N/A |
| Recruiting | Cancer Loyalty Card Study 2 (CLOCS-2) NCT06447064 | Imperial College London | — |
| Not Yet Recruiting | Preoperative Risk Stratification in Endometrial Cancer for Tailoring Lymph Node Staging NCT07368205 | University Hospital Hradec Kralove | — |
| Recruiting | Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial NCT07227077 | Medical College of Wisconsin | N/A |
| Not Yet Recruiting | Tirzepatide in Obesity-Driven Endometrial Cancer NCT07065552 | UNC Lineberger Comprehensive Cancer Center | EARLY_Phase 1 |
| Not Yet Recruiting | SL-28 for Advanced Solid Tumours NCT07341737 | Second Life Therapeutics | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors NCT07383506 | Cogent Biosciences, Inc. | Phase 1 |
| Recruiting | Intrauterine Injection of Type III Collage in FST of EC/AEH NCT07377734 | Wang Jianliu | Phase 2 |
| Recruiting | Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification NCT07319429 | Fudan University | Phase 2 / Phase 3 |
| Not Yet Recruiting | Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer NCT07066969 | European Institute of Oncology | N/A |
| Recruiting | EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in NCT07262619 | Eikon Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer NCT07397624 | Centro di Riferimento Oncologico - Aviano | — |
| Not Yet Recruiting | Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receivi NCT07362147 | Taipei Veterans General Hospital, Taiwan | N/A |
| Recruiting | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants W NCT07444814 | Whitehawk Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of Multiparametric Ultrasound Imaging (mpUS) for People With Endometrial Cancer NCT07318415 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663 | Beijing Tide Pharmaceutical Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participan NCT07166094 | Genmab | Phase 3 |
| Completed | ONSD as an ICP Marker in vNOTES and TLH NCT07250178 | Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital | N/A |
| Recruiting | ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer NCT07270666 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome NCT07220239 | Jessica D. St. Laurent, MD | N/A |
| Recruiting | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer NCT07227168 | Sutro Biopharma, Inc. | Phase 1 |
| Recruiting | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors NCT07182149 | Normunity AccelCo, Inc. | Phase 1 |
| Recruiting | Individualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clin NCT07200466 | Radboud University Medical Center | N/A |
| Recruiting | CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer NCT07278986 | Abramson Cancer Center at Penn Medicine | EARLY_Phase 1 |
| Recruiting | Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer NCT06795009 | Washington University School of Medicine | Phase 1 |
| Not Yet Recruiting | Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Adva NCT07170982 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | The Use of a Novel Vaginal Speculum for Endometrial Biopsies NCT07217353 | Rocky Vista University, LLC | N/A |
| Recruiting | The Effect of Dose and Storage Conditions of Indocyanine Green on Efficacy and Cost in Sentinel Lymph Node Map NCT07380698 | Cukurova University | — |
| Recruiting | A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer NCT07209449 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Not Yet Recruiting | pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer NCT07115927 | University College, London | Phase 2 |
| Recruiting | Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometri NCT07022483 | Daiichi Sankyo | Phase 3 |
| Not Yet Recruiting | Prognosis of METTL-14 in Endometrial Carcinoma NCT06861855 | Assiut University | — |
| Recruiting | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations NCT07109726 | Terremoto Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillanc NCT06995833 | AstraZeneca | — |
| Recruiting | DESTINY-PANTUMOUR04 NCT07124000 | AstraZeneca | — |
| Recruiting | A Study of GV20-0251 in Advanced or Refractory Solid Tumors NCT07106827 | West China Hospital | Phase 1 |
| Not Yet Recruiting | Emergence of Bacterial Resistance to Antibiotics in the Digestive Microbiota of Patients Treated With Anticanc NCT07093593 | Centre Georges Francois Leclerc | N/A |
| Recruiting | Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnair NCT07194551 | University of British Columbia | N/A |
| Recruiting | Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology) NCT07120945 | Medtronic - MITG | N/A |
| Recruiting | A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and NCT07054567 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endo NCT07044336 | AstraZeneca | Phase 3 |
| Not Yet Recruiting | Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometri NCT06073184 | University Health Network, Toronto | Phase 2 |
| Recruiting | OSNA Versus Ultrastaging to Detect Sentinel Lymph Node Metastasis in Endometrial Cancer NCT06935305 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Active Not Recruiting | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations NCT07038369 | Atavistik Bio, Inc | Phase 1 |
| Recruiting | The Better, Harder, Faster, Stronger Study NCT07220512 | Wake Forest University Health Sciences | — |
| Recruiting | Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors NCT06974110 | MOMA Therapeutics | Phase 1 |
| Not Yet Recruiting | Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy NCT06942377 | Peking University People's Hospital | Phase 2 |
| Recruiting | Cohort Study of Intrauterine Diseases NCT07048327 | Wenwen Wang | — |
| Recruiting | Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial NCT07116213 | Xiaorong Hou | N/A |
| Not Yet Recruiting | Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer NCT06977594 | Seoul National University Hospital | N/A |
| Recruiting | An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Trea NCT07041606 | AstraZeneca | — |
| Not Yet Recruiting | Ultrasound Training Program for Gynecologic Cancer Staging in Residents NCT07028229 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Completed | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors NCT06973161 | AstraZeneca | — |
| Recruiting | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Rec NCT06340568 | BioNTech SE | Phase 3 |
| Not Yet Recruiting | Proteomic Analysis of Patients Undergoing Bariatric Surgery NCT06787807 | Universidade Federal de Pernambuco | N/A |
| Recruiting | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187 | Dren Bio | Phase 1 |
| Not Yet Recruiting | Harnessing the Disease Signatures From Endometrium and Menstrual Blood to Identify Avenues for the Treatment o NCT06990971 | Cycle Therapeutics Ltd | — |
| Withdrawn | Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer NCT05850663 | University of Oklahoma | N/A |
| Recruiting | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembro NCT06952504 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DU NCT06890273 | AstraZeneca | — |
| Recruiting | SLV-154 Treatment of Metastatic Solid Tumors NCT06771219 | Solve Therapeutics | Phase 1 |
| Recruiting | Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study NCT07435623 | Tata Memorial Hospital | — |
| Recruiting | a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer NCT06360653 | ARNAS Civico Di Cristina Benfratelli Hospital | N/A |
| Recruiting | QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer NCT06917092 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | A Study of Lorigerlimab in Participants With Advanced Solid Tumors NCT06730347 | MacroGenics | Phase 2 |
| Completed | Serum Trace Element Levels in Some Gynecological Diseases NCT07210918 | Cumhuriyet University | N/A |
| Recruiting | TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC NCT06914297 | Fudan University | Phase 2 |
| Recruiting | A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521 | Tanabe Pharma America, Inc. | Phase 1 / Phase 2 |
| Recruiting | The Clinical Utility of DNA Methylation Testing in Patient-collected Urine and Vaginal Samples to Detect Endom NCT06846775 | University of Aarhus | — |
| Recruiting | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies NCT07327489 | Elephas | — |
| Recruiting | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers NCT06906341 | Corcept Therapeutics | Phase 2 |
| Recruiting | A Study of Ivonescimab in People With Endometrial and Cervical Cancers NCT06925724 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Application of da Vinci SP for Endometrial Cancer Surgical Staging NCT07027046 | National Cancer Institute, Naples | — |
| Recruiting | Metabolic Effect of Exercise and Diet in Endometrial Cancer Patients Eligible for Staging Surgery. NCT07025213 | National Institute of Cancerología | N/A |
| Not Yet Recruiting | Application-Assisted Weight Management in Endometrial Cancer Fertility Preservation NCT06901778 | Peking University People's Hospital | N/A |
| Recruiting | DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as Firs NCT06989112 | AstraZeneca | Phase 3 |
| Recruiting | A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors NCT07029399 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | Generation of Endometrial Carcinoma Organoids NCT07258186 | Regina Elena Cancer Institute | — |
| Recruiting | MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer NCT06677112 | Rachel Miller | N/A |
| Recruiting | Comparison of Transvaginal Paracervical and Transperitoneal Approaches in Lymphadenectomy During v-NOTES Surge NCT06870903 | Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital | N/A |
| Recruiting | A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic C NCT06738966 | Shanghai Best-Link Bioscience, LLC | Phase 1 |
| Not Yet Recruiting | Lipid Mediators & Cancer: Montelukast, SPM, and Almonds NCT06887673 | University of South Florida | EARLY_Phase 1 |
| Completed | GYNecologic Cancer-Related COGnitive Impairment NCT06662435 | Northwestern University | N/A |
| Completed | A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry NCT06925113 | Daiichi Sankyo | — |
| Not Yet Recruiting | A Multi-center Prospective Study on the Oncological and Reproductive Outcomes and Quality of Life in Young Wom NCT06745427 | Region Stockholm | — |
| Recruiting | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors NCT06695845 | Jazz Pharmaceuticals | Phase 2 |
| Recruiting | A Phase 1 Study of LNCB74 in Advanced Solid Tumors NCT06774963 | NextCure, Inc. | Phase 1 |
| Withdrawn | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors NCT06681870 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Recruiting | Trop2-targeted immunoPET Imaging of Solid Tumors NCT06851663 | RenJi Hospital | Phase 2 / Phase 3 |
| Recruiting | Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin NCT06677190 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | A Study of a Weight Loss Intervention in People With Endometrial Cancer NCT06751589 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Not Yet Recruiting | Evaluation of Clinical and Molecular Biomarkers in Immunotherapy Treatment in Gynecologic Cancer NCT06737640 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Active Not Recruiting | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in C NCT06710847 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Recruiting | Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patie NCT06463028 | Faeth Therapeutics | Phase 2 |
| Not Yet Recruiting | Oral Topotecan With Toripalimab for Patients With Endometrial Cancer NCT06548763 | Fudan University | Phase 2 |
| Active Not Recruiting | Impact of Molecular Pathological And Clinical Features for Adjuvant Treatment Selection in Endometrial Cancer: NCT07354087 | Tata Memorial Hospital | — |
| Recruiting | Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot S NCT06603506 | Centre Francois Baclesse | — |
| Recruiting | Avelumab and M1774 in ARID1A-mutated Endometrial Cancer NCT06518564 | Panagiotis Konstantinopoulos, MD, PhD | Phase 2 |
| Not Yet Recruiting | Clinical Studies of Endometrial Cytology and Cervical Methylation Assays in Endometrial Cancer Screening and F NCT06672341 | Yulan Ren | — |
| Not Yet Recruiting | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss NCT06614751 | Danatlas Pharmaceuticals Co., Ltd | Phase 1 |
| Recruiting | Sentinel Lymph Node Mapping With Different Injection Sites of ICG in Endometrium Cancer NCT06656949 | Qilu Hospital of Shandong University | N/A |
| Recruiting | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. NCT06481592 | Iovance Biotherapeutics, Inc. | Phase 2 |
| Terminated | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumo NCT06625515 | Accent Therapeutics | Phase 1 |
| Recruiting | Detection of Endometrial Cancer Through Risk Modelling NCT06268626 | University of British Columbia | — |
| Recruiting | Multimedia Aid for Genetic Testing in Gynecologic Oncology NCT07084168 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Not Yet Recruiting | PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer NCT06549855 | Peking University People's Hospital | N/A |
| Recruiting | ALPINE: Maintenance Letrozole/Abemaciclib NCT06366347 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Implementation of Surgical Safety and Intraoperative Metastasis Identification Through Deep Learning: Multicen NCT06619002 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab NCT06502743 | Yonsei University | Phase 2 |
| Recruiting | A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha NCT06547840 | Epsilogen Ltd | Phase 1 |
| Not Yet Recruiting | Revealing Engagement Patterns Among Endometrial Cancer Patients NCT05998798 | Power Life Sciences Inc. | — |
| Active Not Recruiting | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer NCT06486441 | Gilead Sciences | Phase 3 |
| Recruiting | A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors NCT06533059 | Alterome Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Diet, Hepcidin, and Chemotherapy RDI NCT06483997 | George Washington University | — |
| Not Yet Recruiting | EC_ItaLynch: Mainstreaming the Diagnosis of Lynch Syndrome NCT06501417 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Active Not Recruiting | Methylated Biomarkers Predictive of Endometrial Cancer Risk NCT06800677 | University of Manchester | — |
| Not Yet Recruiting | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors NCT06531486 | NovaOnco Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers NCT06538337 | Jonsson Comprehensive Cancer Center | N/A |
| Completed | Strive Cardio for Endometrial Cancer Survivors NCT06534008 | Jess S. Gorzelitz | N/A |
| Recruiting | Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management NCT05427058 | University of Brawijaya | N/A |
| Recruiting | Pipelle® Under Ultrasound Guidance (PUG) to Investigate Post-menopausal Bleeding. NCT06501846 | Imperial College Healthcare NHS Trust | N/A |
| Recruiting | INSPIRE: a Multi-Cancer Early Detection Study NCT06440018 | Singlera Genomics Inc. | — |
| Recruiting | Molecular Classification in Relation to Prevention of Endometrial Cancer Recurrence and Lifestyle Factors NCT06680791 | Lukas Vanek | — |
| Recruiting | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors NCT06515613 | Context Therapeutics Inc. | Phase 1 |
| Terminated | A Study of PHN-010 in Patients With Advanced Solid Tumors NCT06457997 | Pheon Therapeutics | Phase 1 |
| Active Not Recruiting | Clinical Trial Protocol to Evaluate the Efficacy and Safety of Laparoscopic Surgical Systems for Gynaecologica NCT06598085 | Cornerstone Robotics | N/A |
| Not Yet Recruiting | Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer NCT06475599 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Recruiting | Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p NCT06712472 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 |
| Completed | Single-Port Hysterectomy (R-SPH) Using the Da Vinci SP System in Low-Risk Endometrial Cancer NCT06681831 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Recruiting | Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women NCT06409052 | M.D. Anderson Cancer Center | — |
| Recruiting | Development of a Non-invasive IVD for Endometrial Cancer Screening on High-risk Populations NCT07148154 | MiMARK Diagnostics, S.L. | — |
| Recruiting | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors NCT06239194 | ModeX Therapeutics, An OPKO Health Company | Phase 1 / Phase 2 |
| Recruiting | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors NCT06305962 | Radiopharm Theranostics, Ltd | EARLY_Phase 1 |
| Completed | Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients NCT06007586 | Sichuan Cancer Hospital and Research Institute | Phase 3 |
| Completed | Virtual Reality's Role in See&Treat Hysteroscopy NCT06524934 | Federico II University | N/A |
| Recruiting | Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic NCT06253494 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies NCT06395519 | 858 Therapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Niraparib in High-grade Endometrial Cancer Trial NCT05289648 | Sir Mortimer B. Davis - Jewish General Hospital | EARLY_Phase 1 |
| Terminated | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NCT06299163 | Numab Therapeutics AG | Phase 1 |
| Withdrawn | Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer NCT06385548 | Vall d'Hebron Institute of Oncology | Phase 1 / Phase 2 |
| Recruiting | The Gynecological Cancer Associated Thrombosis (GynCAT) Study NCT06284343 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Terminated | BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced NCT06321068 | Bio-Thera Solutions | Phase 2 / Phase 3 |
| Recruiting | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors NCT06276491 | Xencor, Inc. | Phase 1 |
| Recruiting | ASk Questions in GYnecologic Oncology (ASQ-GYO) NCT06339827 | Ira Winer | N/A |
| Recruiting | The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies NCT06552598 | Tongji Hospital | Phase 1 |
| Recruiting | ImpRoving hEalth behaviourS for LIfe After ENdometrial CancEr Trial NCT06038032 | University of Alberta | N/A |
| Recruiting | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors NCT06218914 | AstraZeneca | Phase 1 |
| Recruiting | Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast NCT06800612 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy NCT06024109 | Aesculap AG | — |
| Completed | Taste Alteration, Sarcopenia, and Malnutrition in Gynecologic Cancer Patients Receiving Carboplatin-Paclitaxel NCT07154966 | Ankara Etlik City Hospital | — |
| Recruiting | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors NCT06257264 | BeiGene | Phase 1 |
| Recruiting | A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470 | MacroGenics | Phase 1 |
| Recruiting | Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis NCT06206083 | National Institute of Cancerología | — |
| Recruiting | Multimodal PET Imaging in the Diagnosis and Treatment of Pelvic Tumors NCT06774209 | Peking Union Medical College Hospital | N/A |
| Not Yet Recruiting | Myeloprotection With Trilaciclib in Pan-cancer Population NCT06297811 | Sun Yat-sen University | Phase 2 |
| Recruiting | Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer NCT06726291 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 4 |
| Recruiting | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors NCT06172478 | Daiichi Sankyo | Phase 2 |
| Terminated | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921 | NiKang Therapeutics, Inc. | Phase 1 |
| Unknown | Vaginal Fluid Collection for Detection of Endometrial Cancer NCT06294886 | Innovis LLC | — |
| Withdrawn | 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy NCT05483023 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors NCT06293898 | SystImmune Inc. | Phase 1 |
| Not Yet Recruiting | Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer NCT06066216 | Fujian Cancer Hospital | Phase 2 |
| Completed | Improved Early Diagnosis in Female Pelvic Cancer With OC Detect NCT06613230 | Region Skane | — |
| Active Not Recruiting | Performance of Ultrasound in Women With Postmenopausal or Abnormal Uterine Bleeding Between White and Black Et NCT06293066 | King's College Hospital NHS Trust | — |
| Unknown | HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China NCT06238284 | Chongqing University Cancer Hospital | — |
| Unknown | Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endome NCT06341855 | The First Hospital of Jilin University | N/A |
| Terminated | PRO1107 in Patients With Advanced Solid Tumors NCT06171789 | Genmab | Phase 1 / Phase 2 |
| Completed | Glove Compression for Chemotherapy-Induced Neuropathy NCT07105553 | Ankara Etlik City Hospital | N/A |
| Recruiting | Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endom NCT05997017 | Aadi Bioscience, Inc. | Phase 2 |
| Recruiting | HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer NCT06014190 | Hansoh BioMedical R&D Company | Phase 2 |
| Active Not Recruiting | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) NCT06132958 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer NCT06180733 | University Medical Center Groningen | Phase 2 |
| Active Not Recruiting | Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil NCT06014580 | Latin American Cooperative Oncology Group | — |
| Recruiting | 3D Printed Custom Applicators for HDR BT (DISCO) NCT06432478 | Royal North Shore Hospital | N/A |
| Recruiting | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors NCT05799274 | Radiopharm Theranostics, Ltd | Phase 1 |
| Recruiting | PROton Therapy for Post Surgical Treatment of GYNecologic Cancer NCT05758688 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Unknown | Radiomics and Radiogenomics Models to Predict Molecular Integrated Risk Classes and Prognostic Factors in Endo NCT06279832 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Not Yet Recruiting | Hyperpolarized 13C MRI for Cancer Immunotherapy NCT05805358 | Chang Gung Memorial Hospital | Phase 2 |
| Recruiting | Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair D NCT05795244 | Yonsei University | Phase 2 |
| Recruiting | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer NCT05542407 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Recruiting | Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy NCT05990426 | Northwestern University | N/A |
| Recruiting | Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignanc NCT05979610 | University of Utah | Phase 2 |
| Completed | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK NCT06036836 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Choices About Genetic Testing And Learning Your Risk With Smart Technology NCT06184867 | Rutgers, The State University of New Jersey | N/A |
| Recruiting | A Cohort Study of Uterine Malignancies NCT05635123 | Women's Hospital School Of Medicine Zhejiang University | — |
| Recruiting | Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) NCT05743517 | Northwestern University | N/A |
| Withdrawn | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer NCT05655598 | Brown University | Phase 1 |
| Recruiting | Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies NCT05914974 | University Hospital Tuebingen | — |
| Completed | Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors NCT05796518 | Wake Forest University Health Sciences | N/A |
| Recruiting | Comparison of Five-year Survival and Disease-free Survival in Patients Diagnosed With Endometrium Cancer Who U NCT06307886 | Gaziosmanpasa Research and Education Hospital | — |
| Recruiting | Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer NCT05974995 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Recruiting | Study of AVZO-021 in Patients With Advanced Solid Tumors NCT05867251 | Avenzo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | Bariatric Education for Women With Obesity and Endometrial Cancer NCT05396794 | University of Oklahoma | — |
| Active Not Recruiting | Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pem NCT05761951 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma NCT05559879 | University of Alabama at Birmingham | Phase 1 / Phase 2 |
| Terminated | Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer NCT05877404 | Wake Forest University Health Sciences | — |
| Recruiting | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Sol NCT05983432 | SystImmune Inc. | Phase 1 |
| Unknown | Early Detection of Endometrial Cancer Using Plasma Cell-free DNA Fragmentomics NCT06083779 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Recruiting | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies NCT05955105 | Innolake Biopharm | Phase 1 / Phase 2 |
| Recruiting | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer NCT05797831 | Kartos Therapeutics, Inc. | Phase 2 / Phase 3 |
| Recruiting | Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for NCT05819892 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors NCT05858736 | OncoC4, Inc. | Phase 1 |
| Unknown | Comparison of Prognosis in Endometrial Cancer Treated With Different Surgical Methods: Laparoscopy, Robotic-as NCT05969405 | Far Eastern Memorial Hospital | — |
| Recruiting | Sentinel Lymph Node in Early-Stage Endometrium Cancer NCT06163963 | Istanbul University | N/A |
| Active Not Recruiting | A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer NCT05634499 | Hoffmann-La Roche | Phase 2 |
| Recruiting | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform NCT05520099 | Elephas | — |
| Recruiting | TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid NCT04969315 | Portage Biotech | Phase 1 / Phase 2 |
| Recruiting | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors NCT05797168 | AstraZeneca | Phase 1 / Phase 2 |
| Unknown | Adherence and Compliance to ERAS in Gynecological Surgery NCT05738902 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | — |
| Recruiting | Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study NCT05857631 | Tata Memorial Centre | N/A |
| Recruiting | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Seque NCT06028724 | Centro di Riferimento Oncologico - Aviano | — |
| Recruiting | Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN) NCT05855941 | Region Västerbotten | — |
| Terminated | A Biomarker Screening Protocol for Participants With Solid Tumors NCT05891197 | Lyell Immunopharma, Inc. | — |
| Active Not Recruiting | Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer NCT05824481 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | Genetic Testing in African Americans NCT05591131 | Augusta University | N/A |
| Recruiting | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors NCT05787587 | IDEAYA Biosciences | Phase 1 |
| Recruiting | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recur NCT05611931 | Karyopharm Therapeutics Inc | Phase 3 |
| Unknown | Developing a MRI-based Deep Learning Model to Predict MMR Status NCT05783986 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Active Not Recruiting | Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention NCT05677048 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981 | Sairopa B.V. | Phase 1 |
| Unknown | Unusual Infiltrative Patterns of Malignant Cells in Endometrial Carcinoma and Immunohistochemical Expression o NCT05755893 | Assiut University | — |
| Unknown | DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer NCT05728814 | Grupo Español de Investigación en Cáncer de Ovario | — |
| Unknown | Non-Invasive Diagnosis of Endometrial Cancer NCT05737797 | Assistance Publique - Hôpitaux de Paris | N/A |
| Unknown | Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening Tools NCT05697601 | Hasanuddin University | — |
| Completed | Prolonged Grief and Perception of Femininity in Gynecological Cancer Patients NCT05529303 | Kevser Pamuk | N/A |
| Unknown | Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer NCT05446324 | UMC Utrecht | Phase 3 |
| Recruiting | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select S NCT05683418 | Totus Medicines | Phase 1 |
| Active Not Recruiting | Activity and Cancer Survivorship Exercise Pilot NCT07283029 | University of Iowa | N/A |
| Unknown | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and End NCT05812677 | Shanghai Yunying Medical Technology | EARLY_Phase 1 |
| Completed | FitEx for Endometrial Cancer Survivors: Initial Efficacy NCT05737745 | Carilion Clinic | N/A |
| Unknown | Endometrial Changes in Breast Cancer Women. NCT05717634 | Regina Elena Cancer Institute | — |
| Unknown | AMT-151 in Patients With Selected Advanced Solid Tumours NCT05498597 | Multitude Therapeutics Inc. | Phase 1 |
| Recruiting | Improving Endometrial Cancer Assessment by Combining Genomic Profiling and Surgical Assessment NCT06354738 | University Hospital, Gasthuisberg | N/A |
| Unknown | From Fetal-maternal Interface Immune Tolerance to Endometrial Cancer Immune Escape: Potential Targets for Immu NCT06273878 | Regina Elena Cancer Institute | — |
| Active Not Recruiting | First in Human Study of IMGN151 in Recurrent Gynaecological Cancers NCT05527184 | AbbVie | Phase 1 |
| Recruiting | A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer NCT05691010 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Completed | Iron Prehabilitation in Endometrial Cancer NCT06049693 | National and Kapodistrian University of Athens | Phase 4 |
| Unknown | Staging Endometrial caNcer Based on molEcular ClAssification NCT05707312 | Clinica Universidad de Navarra, Universidad de Navarra | — |
| Completed | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors NCT05538572 | Prelude Therapeutics | Phase 1 |
| Recruiting | Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER NCT05640999 | Canadian Cancer Trials Group | Phase 2 |
| Recruiting | Immunotolerance in Endometrial Cancer and at the Maternal-fetal Interface: Immunological Profiling of the Tumo NCT06250010 | Regina Elena Cancer Institute | — |
| Recruiting | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366 | Genmab | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903 NCT06846099 | Risen (Suzhou) Pharma Tech Co., Ltd. | Phase 1 |
| Completed | Strain-elastography in Endometrial Cancer NCT06623916 | Alper seyhan | — |
| Not Yet Recruiting | Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification NCT05524389 | Peking Union Medical College Hospital | Phase 3 |
| Terminated | Oral AMXT 1501 Dicaprate in Combination With IV DFMO NCT05500508 | Aminex Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer NCT05876130 | Samsung Medical Center | N/A |
| Not Yet Recruiting | Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer NCT05550558 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Development and Management of Registry in Patients With Gynecologic Cancer in Korea NCT05912972 | Asan Medical Center | — |
| Active Not Recruiting | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectab NCT05572684 | NextCure, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Laser Treatment of Genito-urinary Syndrome in Women NCT03238053 | Herning Hospital | N/A |
| Completed | Comparison Between High and Low Level Para-aortic Lymphadenectomy in High and Intermediate Risk Endometrial Ca NCT07306195 | Ahmed Aouf | N/A |
| Terminated | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers NCT05082025 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cav NCT05378152 | Royal College of Surgeons, Ireland | N/A |
| Recruiting | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tu NCT05489211 | AstraZeneca | Phase 2 |
| Not Yet Recruiting | Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation NCT05489848 | Fudan University | Phase 2 / Phase 3 |
| Recruiting | BP1001-A in Patients With Advanced or Recurrent Solid Tumors NCT04196257 | Bio-Path Holdings, Inc. | Phase 1 |
| Recruiting | A Study of XMT-1660 in Participants With Solid Tumors NCT05377996 | Mersana Therapeutics | Phase 1 |
| Active Not Recruiting | Improving Care After Inherited Cancer Testing NCT04763915 | Vanderbilt-Ingram Cancer Center | N/A |
| Terminated | Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP NCT05454358 | Fudan University | Phase 2 / Phase 3 |
| Active Not Recruiting | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies NCT05032040 | Xencor, Inc. | Phase 2 |
| Terminated | Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer NCT05332483 | Sunnybrook Health Sciences Centre | Phase 1 |
| Completed | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1 NCT05383482 | Laekna Limited | Phase 1 / Phase 2 |
| Recruiting | Comprehensive Outcomes for After Cancer Health NCT05349227 | Pack Health | N/A |
| Completed | Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endo NCT05364905 | ARCAGY/ GINECO GROUP | — |
| Recruiting | cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease NCT05366881 | Adela, Inc | — |
| Unknown | Magnetic Resonance Fingerprinting in the Imaging of Endometrial Cancer NCT05807672 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Completed | Michigan Genetic Hereditary Testing (MiGHT) NCT05162846 | University of Michigan Rogel Cancer Center | N/A |
| Active Not Recruiting | Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line NCT05201547 | ARCAGY/ GINECO GROUP | Phase 3 |
| Terminated | (VELA) Study of BLU-222 in Advanced Solid Tumors NCT05252416 | Blueprint Medicines Corporation | Phase 1 |
| Terminated | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors NCT05194735 | Alaunos Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving NCT04997096 | Dana-Farber Cancer Institute | N/A |
| Completed | Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients NCT05320757 | The University of Hong Kong | EARLY_Phase 1 |
| Terminated | Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer NCT05263492 | Virginia Commonwealth University | Phase 2 |
| Terminated | A Study to Investigate LYL797 in Adults With Solid Tumors NCT05274451 | Lyell Immunopharma, Inc. | Phase 1 |
| Unknown | Uterine Manipulator in Endometrial Cancer Surgery: Pro MUCEI Study NCT05242276 | Instituto de Investigacion Sanitaria La Fe | — |
| Terminated | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors NCT05169437 | Tempus AI | Phase 2 |
| Unknown | Host DNA Methylation for Endometrial Cancer Screening NCT05290415 | Lei Li | — |
| Unknown | DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening NCT05290922 | Lei Li | — |
| Recruiting | Single cEll pRofiling PErsistaNce To ImmuNothErapy NCT06680739 | Vall d'Hebron Institute of Oncology | Phase 2 |
| Unknown | Evaluation of MCM5 in Postmenopausal Bleeding Patients NCT05287048 | Arquer Diagnostics Ltd | — |
| Terminated | Study of Copanlisib and Ketogenic Diet NCT04750941 | Columbia University | Phase 2 |